Background

Current Positions

Professor of Dermatology, Newcastle University and Honorary Consultant Dermatologist Newcastle Hospitals NHS Foundation Trust (from 2001)

Director, Newcastle MRC/EPSRC Molecular Pathology Node (from 2016)

Roles and Responsibilities 

2018 - Board member European Dermatology Forum
2017- Board member International Eczema Council
2011 - Chair, Research Committee, British Association of Dermatologists Biologic Interventions Register (BADBIR)
2008 - 2015 Board Member,  European Society for Dermatological Research (ESDR)
2013 - 2017 Chair, UK Translational Research Network in Dermatology (UK TREND)
2013-2014 - President, European Society for Dermatological Research (ESDR)

Qualifications

FRCP, Royal College of Physicians, London, 1999
MD University of London, 1995
MBBS University of London, 1983
BSc Hons (Intercalated) University of London, 1980

Previous Positions

• 2005-2008 Head of School, Clinical and Laboratory Sciences, Newcastle University
• 2001-2004 Wellcome Trust Research Leave Fellowship for Clinical Academics
• 1995-2001 Senior Lecturer, University of Newcastle upon Tyne and Consultant Dermatologist, Royal Victoria Infirmary, Newcastle upon Tyne 
• 1993-1994 Senior Registrar, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne
• 1990-1992 Research Fellow and Lecturer, Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
• 1987-1990 Registrar, Department of Dermatology, Bristol Royal Infirmary, Avon

Google Scholar: Click here.

Research

Research Interests

• Translational and systems biology research in dermatology and skin biology
• Stratified medicine for psoriasis and atopic eczema; and mechanism of action of anti-psoriatic therapies: biologics (PSORT) and ultraviolet B (UVB, Rosetrees Inter-disciplinary award)
• Clinical trials, molecular genetics and disease models of atopic eczema.
• Keratinocyte cell signalling
• UV and wound healing signalling responses

My laboratory is interested translatonal research of inflammatory skin disease (specifically psoriasis and atopic eczema).  We have a particular interest in gaining insights into disease mechanisms and the pathways involved in clearing psoriasis.  We are part of a consortium led by the University of Manchester that has begun work to apply a stratified medicine approach to psoriasis and predict which biological therapy is best suited for an individual patient.

The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium is a unique partnership between five UK universities: Manchester, Newcastle, King’s College London, Queen Mary and Liverpool, 10 pharmaceutical and diagnostics companies and the Psoriasis Association and NHS partners representing patients.

We also study the mechanism of action of anti-psoriatic therapies including UVB (supported by the Rosetrees Trust and Newcastle's NIHR Biomedical Research Centre), as we think this may provide important insights into disease pathogenesis and lead to the identification of new therapeutic targets. We are interested in understanding the regulation of diverse cellular responses induced by UVR. These studies are supported by important collaborations with Professor Peter Farr and Dr Sophie Weatherhead, Dermatology RVI.

On-going studies focus on the induction of apoptosis by UVR in the clearance of psoriatic plaques, the interaction of calcineurin inhibitors (ciclosporin and tacrolimus) with the Ca2 /calcineurin/NFAT pathway in human keratinocytes, and the role of mitochondria in mediating the therapeutic action of dithranol in psoriasis.

We have conducted important investigator-led clinical trials in atopic eczema (e.g. REF 2014 impact case) and have contributed to increased understanding of the molecular genetics of atopic eczema. We have set up a filaggrin-knockdown skin equivalent model of atopic eczema which we are using to investigate therapeutic targets (through a BBSRC Case studentship with Stiefel/GSK).

Another area of focus is keratinocyte cell signalling, particularly in response to environmental insults such as ultraviolet radiation, wounding (in collaboration with Prof Jeremy Lakey, through a EPSRC/BBSRC Innovate UK project).

Since 2016, I have been the Director of the Newcastle MRC Molecular Pathology Node, which is aiming to reinvigorate diagnostic research and development within the NHS, enhancing training and building capacity.  We are utilising the Proximity laboratory to develop tissue biomarkers of clinical response and image these multi-dimentionally (Vectra).   

Research Group Members:

• Dr Pawan Gulati, Senior Research Associate
• Dr Graham Smith, PSORT post-doctoral systems biologist
• Dr Emma Burton, PSORT project manager
• Esme Nichols, Research Technician
• Dr Henry Graham, NIHR clinical academic fellow
• Dr Guarav Dhawan, BRC/Rosetrees Clinical Research Fellow
• Rachel Roberts, PhD Student
• Ashley Rider, Psoriasis Association, PhD Student

Postgraduate Supervision

Funding

• MRC

• NIHR Biomedical Research Centre (BRC) 

• British Skin Foundation

• EPSRC/BBSRC Innovate UK

• Rosetrees Foundation

Teaching

We place a strong emphasis on undergraduate teaching and postgraduate training.  We run an active weekly programme both within ICM and dermatology (clinical and basic science journal clubs, research in progress meetings) and play a key role in the MRes in Medical and Molecular Biosciences. 

Many of our clinical trainees pursue higher research degrees funded through external nationally funded fellowships (Wellcome, MRC, Action Medical Research, British Skin foundation) and our PhD students have secured fellowships (European Commission) and post-doctoral positions  (eg Settembre lab, TIGEM, Pozzuoli, Italy; Khavari lab, Stanford; Buck Institute, San Francisco; NIH, Bethesda; University of Chicago). 

In 2006/2007, we were one of only three units in England and Wales to be awarded academic clinical fellowships in dermatology through a national competition and a Walport/NIHR Lectureship was recently established.

Since 2008, three of our clinical trainees have gone on to secure prestigious Wellcome Intermediate Fellowships, one in Dundee and two in Newcastle.  Two of these investigators were recently awarded Senior Wellcome Fellowships in Clinical Science (one in Dundee and one in Newcastle).

Postgraduate Student Supervision - Current

• Rachel Roberts (PhD)
• Dr Guarav Dhawan (MD)
• Ashley Rider (PhD)

Postgraduate Student Supervision - Completed

• Martina Elias (PhD), 2017*

• Emma Woodward PhD, 2017*

• Keith Wu (PhD), 2015*

• Laura Hudson PhD, 2014*

• Aparna Sinha MD, 2014*

• Darren Johnson PhD, 2013*

• Nicola Fullard PhD, 2013

• Alison Forrester PhD, 2012*

• Sophie Weatherhead PhD, 2011*

• Shanji Anthony MPhil, 2009*

• Sarah Milner PhD, 2009*

• Baba Taal PhD, 2009*

• Sara Brown MD with commendation, 2008

• Muzz Haniffa PhD, 2008

• Ross Flockhart PhD, 2007*

• Simon Meggitt MD with distinction, 2006*

• Philip Hampton PhD, 2006*

• Sandy McBride MD with commendation, 2002*

• Wael Al-Daraji MD, 2002*

• Paula Fearon PhD, 2002*

*Primary supervisor 

NIHR Clinical Academic Training - Current

• Henry Grantham, Clinical Academic Fellow

RECENT INVITED LECTURES AT NATIONAL/INTERNATIONAL CONFERENCES

2018

Psoriasis Association, 50th Anniversary; Psoriasis: translating innovation into personalised care: “Systems biology and computational modelling for psoriasis: future perspectives”
Euroderm Excellence, Nice: The current treatment landscape
EADV, Paris; Training and Educational Forum: Atopic dermatitis: Epidemiology and Pathophysiology
ESDR-EADV Summer Research Course, Naples: Transcriptomic analysis of psoriasis following UVB and biologic therapy
Bionow Precision Medicine Conference, Leeds: Taking biomarker discovery through to implementation
Dubai Academy of Dermatology Meeting: Navigating the psoriasis armamentarium in 2018, an holistic approach
Dubai Academy of Dermatology Meeting: P4 medicine for psoriasis and inflammatory skin disease

2017

Immune Mediated Inflammatory Diseases (IMID) Summit: "Using real world evidence to inform best-practice: psoriasis"

Euroderm: "Psoriasis, navigating the treatment armamentarium"

European Association for Dermato-Venereology (EADV) annual meeting: "Atopic eczema clinical features and treatments"

2016

RCP Advanced Medicine Course, Abu Dhabi: Translation of Clinical Research into
Personalised Medicine

British Society for Rheumatology, Glasgow: “Newer therapeutic agents for psoriasis: a dermatological perspective

Psoriasis Association AGM, Northampton: “Psoriasis Stratification to Optimise Relevant Therapy (PSORT)”.

European Association for Dermato-Venereology (EADV) Fostering Course, Rotterdam, The Netherlands: “How to run a clinical trial”.

British Association of Dermatologists (BAD) Annual meeting, Birmingham Derm School: Translational Dermatology

2015

BSID, Southampton, UK: UK TREND  - an opportunity for research

World Congress of Dermatology, Vancouver, Canada: A systems biology approach to understanding the mechanism of action of UVB phototherapy in psoriasis

World Congress of Dermatology, Vancouver, Canada: Systems dermatology: insights into epidermal remodeling in psoriasis

BAD Annual Meeting, Manchester, UK: Research across the academic industrial interface

BAD Annual Meeting, Manchester, UK: Engaging with UK Translational Research Network in Dermatology

European Dermatoepidemiology Network, ESDR, Rotterdam, Netherlands: Personalised Medicine for Skin Diseases

EADV Annual Meeting, Copenhagen, Denmark: A critical appraisal of biologics for psoriasis

Real World Evidence Conference (Janssen), London, UK:  BADBIR and PSORT: a pharmacovigilance registry leading onto a stratified medicine initiative

‘Allergy & the Skin’ Study Day, London, UK How should we manage patients with difficult atopic eczema

2014

EADV Annual Meeting, Amsterdam, The Netherlands: “Personalised medicine for inflammatory skin disease”

BAD Annual Meeting, Glasgow, UK: “Physiology and importance of IL-17 in the pathogenesis of psoriasis”

ESDR/EADV Summer Research School, Helsinki, Finland: “Cutaneous transcriptomics”

RCP of Edinburgh Symposium on Dermatology: “How should we manage patients with difficult eczema?”

KSID, Seoul, South Korea: “Mechanistic insight into epidermal remodelling in psoriasis: a systems biology approach”

2013

Leo Research Foundation Prize Award Ceremony, Copenhagen, Denmark: “The dynamic platform of translational research: from bench to bedside and back again”

ESDR Future Leaders Academy, Florence, Italy, A journey through Translation

Medicine and me symposium, RSM, London: “Key advances in psoriasis research” http://www.rsmvideos.com/videoPlayer/?vid=436&class=videoThumb

EADV meeting, Istanbul: “Keratinocyte apoptosis in remodeling and clearance of psoriatic plaques” and “Efficacy of phototherapy in childhood and adult atopic eczema”

BAD Annual Meeting, Liverpool: “Future psoriasis therapy beyond TNF-a blockade” and “Systemic treatment for severe adult atopic dermatitis”

Psoriasis International Network Congress, Paris: “Resistant palmoplantar pustulosis” and “The impact and management of psoriasis in pregnancy”

Irish Association of Dermatologists Meeting, Belfast

RSM Michael Fuell Memorial Lecture, London: “Systems biology in dermatology: mechanistic insight into epidermal remodelling in psoriasis”

Publications

• Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds N, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, BSTOP study group, PSORT consortium. Defining the therapeutic range for adalimumab and predicting response in psoriasis: amulticenter prospective observational cohort study. Journal of Investigative Dermatology 2019, 139(1), 115-123.
• Grantham HJ, Reynolds NJ. The devil is in the data: differences in drug persistence between SNIIRAM, the French national health insurance database, and psoriasis biologics intervention registers. British Journal of Dermatology 2019, 180(1), 8-10.
• Watson N, Wu K, Farr P, Reynolds NJ, Hampton PJ. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. British Journal of Dermatology 2019, 180(1), 195-196.
• Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M, Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR. A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. Journal of Investigative Dermatology 2018, 139(1), 100-107.
• Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Koks S, Mrowietz U, Puig L, Reynolds N, Tan EST, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csorgo Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F. Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology 2018, Epub ahead of print.
• Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology 2018, (ePub ahead of Print).
• Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB, BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 2018, Epub ahead of print.
• Simpson EL, Reynolds NJ, Flohr C, Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Irvine AD. Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’”. Journal of the American Academy of Dermatology 2018, 79(2), e25-e26.
• Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology 2018, 138(3), 534-541.
• Brass D, Fouweather T, Stocken D, Macdonald C, Wilkinson J, Lloyd JJ, Farr PM, Reynolds NJ, Hampton PJ. An observer blinded randomised controlled pilot trial comparing localised immersion psoralen ultraviolet A (PUVA) with localised narrowband ultraviolet B (NBUVB) for the treatment of palmar hand eczema. British Journal of Dermatology 2017, Accepted article.
• Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, Mcelhone K, Smith CH, Reynolds NJ, Griffiths CEM. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology 2017, 177(5), 1410-1421.
• Grantham HJ, Stocken DD, Reynolds NJ. Doxycycline: A first-line treatment for bullous pemphigoid?. The Lancet 2017, 389(10079), 1586-1588.
• Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Duffin KC, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Huffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Lohr S, Mrowietz U, Muller-Nurayid M, Nothen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN. Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics 2017, 26(21), 4301-4313.
• Al-Jefri K, Newbury-Birch D, Muirhead CR, Gilvarry E, Araujo-Soares V, Reynolds NJ, Kaner E, Hampton PJ. High prevalence of alcohol use disorders in patients with inflammatory skin diseases. British Journal of Dermatology 2017, 177(3), 837-844.
• Iskandar IYK, Ashcroft DM, Warren RB, Evans I, Mcelhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM. Patterns of biologic therapy use in the management of psoriasis: Cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 2017, 177(5), 1297-1307.
• Taylor S, Huang Y, Mallet G, Stathopoulou C, Felizardo TC, Sun MA, Martin EL, Zhu N, Woodward EL, Elias M, Scott J, Reynolds NJ, Paul WE, Fowler DH, Amarnath S. PD-1 regulates KLRG1⁺ group 2 innate lymphoid cells. Journal of Experimental Medicine 2017, 214(6), 1663.
• Elias MS, Long HA, Newman CF, Wilson PA, West A, McGill PJ, Wu KC, Donaldson MJ, Reynolds NJ. Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema. Journal of Allergy and Clinical Immunology 2017, 140(5), 1299-1309.
• Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ. Treatment of moderate-to-severe atopic eczema in adults within the UK: Results of a national survey of dermatologists. British Journal of Dermatology 2017, 176(6), 1617-1623.
• Samuel RJ, Reynolds NJ. Ustekinumab for severe atopic dermatitis: an important negative study. British Journal of Dermatology 2017, 177(2), 339-341.
• Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, Bieber T, Vestergaard C, Brown SJ, Cork MJ, Drucker AM, Eichenfield LF, Foelster-Holst R, Guttman-Yassky E, Nosbaum A, Reynolds NJ, Silverberg JI, Schmitt J, Seyger MMB, Spuls PI, Stalder J-F, Su JC, Takaoka R, Traidl-Hoffmann C, Thyssen JP, van der Schaft J, Wollenberg A, Irvine AD, Paller AS. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology 2017, 77(4), 623-633.
• Wu KCP, Reynolds NJ. CARD14 mutations may predict response to antitumour necrosis factor-α therapy in psoriasis: a potential further step towards personalized medicine. British Journal of Dermatology 2016, 175(1), 17-18.
• Hampton P, Al-Jefri K, Muirhead C, Newbury-Birch D, Kaner K, Gilvarry E, Araujo-Soares V, Reynolds N. Examining the prevalence of alcohol use disorders in patients with skin disease. In: British Skin Foundation, Skin Deep - 20 Years of Research, 20th Anniversary Conference. 2016, London: Wiley-Blackwell Publishing Ltd.
• Jabbar-Lopez ZK, Weatherhead SC, Reynolds NJ. Kidney disease in moderate-to-severe psoriasis: A critical appraisal. British Journal of Dermatology 2016, 174(2), 267-270.
• Elias M, Long H, Brown S, Donaldson M, Reynolds N. Methotrexate regulates late epidermal differentiation and barrier function in normal and filaggrin-deficient models and in atopic eczema in vivo. In: BSID Annual Meeting. 2016, Dundee: Wiley-Blackwell Publishing Ltd.
• Reynolds NJ, Sinha A, Lonsdale-Eccles A, Fearon P, Forrester A, Elias MS, Todd C, Allain F. Role of cyclophilin B in regulating human keratinocyte differentiation, growth and homeostasis and in mediating the therapeutic effects of ciclosporin in atopic eczema. In: British Skin Foundation, Skin Deep - 20 Years of Research, 20th Anniversary Conference. 2016, London, U.K: Wiley-Blackwell Publishing Ltd.
• Reynolds NJ, Sinha A, Elias MS, Meggitt SJ. Translating translation into patient benefit for atopic eczema. British Journal of Dermatology 2016, 175(Suppl. S2), 8-12.
• Iskandar I, Ashcroft DM, Warren RB, Yiu ZZN, McElhone K, Lunt M, Barker JNWN, Burden AD, Ormerod AD, Reynolds NJ, Smith CH, Griffiths CEM. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology 2015, 173(2), 510-518.
• Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CEM, BADBIR Study Grp. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology 2015, 135(11), 2632-2640.
• Griffiths CEM, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, Warren RB, Barker JNWN, PSORT Consortium. Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology 2015, 135(12), 2903-2907.
• Healy E, Brown SJ, Langan SM, Nicholls SG, Shams K, Reynolds NJ, UK TREND. Identification of translational dermatology research priorities in the UK: results of an electronic Delphi exercise. British Journal of Dermatology 2015, 173(5), 1191-1198.
• Wu K, Morse M, Donaldson M, Reynolds N. Inhibition of bromodomain extraterminal proteins differentially regulates cytokine production in an in vitro skin inflammation model relevant to psoriasis. In: British Society for Investigative Dermatology Annual Meeting 2015. 2015, Southampton, UK: Wiley-Blackwell.
• Anstey A, Reynolds NJ. What does the BJD now stand for? A position statement. British Journal of Dermatology 2015, 172(6), 1463-1465.
• Coates LC, Walsh J, Haroon M, Fitzgerald O, Aslam T, Al-Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions from Existing tools. Arthritis Care and Research 2014, 66(9), 1410-1416.
• Forrester AR, Elias MS, Woodward EL, Graham M, Williams FM, Reynolds NJ. Induction of a chloracne phenotype in an epidermal equivalent model by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on aryl hydrocarbon receptor activation and is not reproduced by aryl hydrocarbon receptor knock down. Journal of Dermatological Science 2014, 73(1), 10-22.
• Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: A case report and review of the literature. Dermatology and Therapy 2014, 4(2), 145-156.
• Jabbar-Lopez ZK, Wu KC, Reynolds NJ. Newer agents for psoriasis in adults. BMJ 2014, 349, g4026.
• Reynolds NJ. One hundred and twenty-five years and counting: into an era of systems dermatology. British Journal of Dermatology 2014, 171(6), 1279-1281.
• Coates LC, Aslam T, Al-Balushi F, Burden AD, Burden-The E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Psoriatic arthritis screening tools: Study design and methodologic challenges - reply from authors. British Journal of Dermatology 2014, 170(4), 995-996.
• Saunders SP, Goh CSM, Brown SJ, Palmer CNA, Porter RM, Cole C, Campbell LE, Gierlinski M, Barton GJ, Schneider G, Balmain A, Prescott AR, Weidinger S, Baurecht H, Kabesch M, Gieger C, Lee YA, Tavendale R, Mukhopadhyay S, Turner SW, Madhok VB, Sullivan FM, Relton C, Burn J, Meggitt S, Smith CH, Allen MA, Barker JNWN, Reynolds NJ, Cordell HJ, Irvine AD, McLean WHI, Sandilands A, Fallon PG. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. Journal of Allergy and Clinical Immunology 2013, 132(5), 1121-1129.
• Jans R, Mottram L, Johnson DL, Brown AM, Sikkink S, Ross K, Reynolds NJ. Lysophosphatidic Acid Promotes Cell Migration through STIM1- and Orai1-Mediated Ca²⁺i Mobilization and NFAT2 Activation. Journal of Investigative Dermatology 2013, 133(3), 793-802.
• Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, Nasr IS, Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS, Williams HC. Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine 2013, 368(18), 1695-1703.
• Wu KCP, Reynolds NJ. Predicting response to anti-interleukin 12/23 treatment in psoriasis. British Journal of Dermatology 2013, 169(2), 240-241.
• Weatherhead SC, Farr PM, Reynolds NJ. Spectral effects of UV on psoriasis. Photochemical & Photobiological Sciences 2013, 12(1), 47-53.
• Fullard N, Moles A, O'Reilly S, van Laar JM, Faini D, Diboll J, Reynolds NJ, Mann DA, Reichelt J, Oakley F. The c-Rel Subunit of NF-κB Regulates Epidermal Homeostasis and Promotes Skin Fibrosis in Mice. American Journal of Pathology 2013, 182(6), 2109-2120.
• Hampton PJ, Jans R, Flockhart R, Parker G, Reynolds NJ. Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). Journal of Cellular Physiology 2012, 227(4), 1529-1537.
• Wu K, Reynolds NJ. Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. British Journal of Dermatology 2012, 166(1), 7-11.
• Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CEM, BADBIR Study Grp. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology 2012, 166(3), 545-554.
• Meggitt SJ, Anstey AV, Mustapa MFM, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. British Journal of Dermatology 2011, 165(4), 711-734.
• Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, Carmichael AJ, Carr MM, Drummond A, Natarajan S, Smith CH, Reynolds NJ, Meggitt SJ. Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology 2011, 131(10), 1981-1986.
• Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, Lloyd JL, Wipat A, Reynolds NJ. Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation. Journal of Investigative Dermatology 2011, 131(9), 1916-1926.
• Fearon P, Lonsdale-Eccles AA, Ross OK, Todd C, Sinha A, Allain F, Reynolds NJ. Keratinocyte secretion of cyclophilin B via the constitutive pathway is regulated through its cyclosporin-binding site. Journal of Investigative Dermatology 2011, 131(5), 1085-1094.
• Wahie S, McColl E, Reynolds NJ, Meggitt SJ. Measuring disease activity and damage in cutaneous lupus erythematosus. British Journal of Dermatology 2011, 164(1), 221-222.
• Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, Chair Guideline Grp. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 2009, 161(5), 987-1019.
• Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, McLean WH, Cordell HJ, Reynolds NJ. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. British Journal of Dermatology 2009, 161(4), 884-889.
• Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. British Journal of Cancer 2009, 101(8), 1448-1455.
• Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, Wilson IJ, Burn J, Reynolds NJ, McLean WH, Cordell HJ. Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. Journal of Allergy and Clinical Immunology 2008, 121(4), 940-946.
• Flockhart R, Diffey BL, Farr PM, Lloyd JJ, Reynolds NJ. NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultravioloet radiation exposure. FASEB Journal 2008, 22(12), 4218-4227.
• Brown SJ, Sandilands A, Zhao Y, Liao H, Relton CL, Meggitt SJ, Trembath RC, Barker JNWN, Reynolds NJ, Cordell HJ, McLean WHI. Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. Journal of Investigative Dermatology 2008, 128(6), 1591-1594.
• Ross K, Whitaker M, Reynolds NJ. Agonist-induced calcium entry correlates with STIM1 translocation. Journal of Cellular Physiology 2007, 211(3), 569-576.
• Weatherhead S, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. British Journal of Dermatology 2007, 156(2), 346-351.
• Hampton PJ, Ross OK, Reynolds NJ. Increased nuclear β-catenin in suprabasal involved psoriatic epidermis. British Journal of Dermatology 2007, 157(6), 1168-1177.
• Barker JNWN, Palmer CNA, Zhao Y, Liao H, Hull PR, Lee SP, Allen MH, Meggitt SJ, Reynolds NJ, Trembath RC, McLean WHI. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. Journal of Investigative Dermatology 2007, 127(3), 564-567.
• Weatherhead S, Robson SC, Reynolds NJ. Pregnancy plus - Eczema in pregnancy. British Medical Journal 2007, 335(7611), 152-154.
• Weatherhead S, Robson SC, Reynolds NJ. Pregnancy plus - Management of psoriasis in pregnancy. British Medical Journal 2007, 334(7605), 1218-1220B.
• Brown S, Reynolds NJ. Atopic and non-atopic eczema. British Medical Journal 2006, 332(7541), 584-588.
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial. The Lancet 2006, 367(9513), 839-846.
• Ekelund E, Saaf A, Tengvall-Linder M, Melen E, Link J, Barker J, Reynolds NJ, Meggitt SJ, Kere J, Wahlgren C-F, Pershagen G, Wickman M, Nordenskjold M, Kockum I, Bradley M. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. American Journal of Human Genetics 2006, 78(6), 1060-1065.
• Veal CD, Reynolds NJ, Meggitt SJ, Allen MH, Lindgren CM, Kere J, Trembath RC, Barker JNWN. Absence of association between asthma and high serum immunoglobulin E associated GPRA haplotypes and adult atopic dermatitis [8]. Journal of Investigative Dermatology 2005, 125(2), 399-401.
• Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, Finlay AY, Grifitths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology 2005, 153(3), 486-497.
• Hampton PJ, Reynolds NJ. Calcineurin inhibitors for the treatment of skin disease: How do they work?. Clinical and Experimental Allergy 2005, 35(5), 549-550.
• McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB Journal 2005, 19(8), 1012-1014.
• McBride SR, Walker P, Reynolds NJ. Optimising the frequency of outpatient short contact dithranol treatment: a randomised, within patient controlled trial. British Journal of Dermatology 2003, 149(6), 1259-1265.
• Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. Journal of Investigative Dermatology 2002, 118(5), 779-788.
• Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clinical and Experimental Dermatology 2001, 26(5), 369-375.
• Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial. Lancet 2001, 357(9273), 2012-2016.
• Todd C, Reynolds NJ. Up-regulation of p21(WAF1) by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. American Journal of Pathology 1998, 153(1), 39-45.